文献速递头颈与中枢神经肿瘤

贝伐珠单抗可能改善胶质母细胞瘤生活质量但不延长总生存:一项流行病学研究

Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究回顾性分析瑞士苏黎世州2010-2014年诊断的310例胶质母细胞瘤患者,并与2005-2009年数据比较。在IDH野生型患者中,贝伐珠单抗使用率从19%升至49%,但中位总生存无显著改善(13.5个月 vs 11.3个月,P=0.761)。二线治疗中贝伐珠单抗组83%患者皮质类固醇基线剂量减少过半,显著高于无贝伐珠单抗组的48%(P=0.007)。

要点

  • 贝伐珠单抗使用率增加未改善IDH野生型胶质母细胞瘤患者的总生存。
  • 二线贝伐珠单抗治疗与皮质类固醇剂量显著减少相关。
  • 该人群水平研究不支持贝伐珠单抗改善胶质母细胞瘤生存的假设。

核心结论

  • 这项流行病学研究未能支持2010年以来贝伐珠单抗使用大幅增加改善了胶质母细胞瘤生存的假设,但可能通过减少皮质类固醇使用获得临床获益。

研究设计与样本

  • 回顾性分析2010-2014年瑞士苏黎世州诊断的310例胶质母细胞瘤患者的流行病学、分子遗传学和临床数据,并与2005-2009年数据比较,采用log-rank检验和Cox比例风险模型。

主要发现

  • IDH野生型患者(N=248)2010-2014年中位总生存为13.5个月,2005-2009年为11.3个月(P=0.761)。
  • IDH野生型队列中,贝伐珠单抗任何时间使用率从2005-2009年的19%增至2010-2014年的49%。
  • 多因素分析未发现任何时间贝伐珠单抗暴露与生存相关。
  • 二线治疗中,贝伐珠单抗组83%患者皮质类固醇基线剂量减少过半,无贝伐珠单抗组为48%(P=0.007)。

临床怎么用

  • 对于胶质母细胞瘤患者,贝伐珠单抗不应以延长总生存为目的使用,但可考虑用于减少皮质类固醇需求。

局限性

  • 研究为小样本回顾性队列,可能影响统计效能和因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The vascular endothelial growth factor antibody bevacizumab (Avastin®), received approval for the treatment of recurrent glioblastoma in many countries including the USA and Switzerland, but not the European Union, in 2009. Here, we explored the hypothesis that the approval of bevacizumab improved outcome with glioblastoma on a population level. PATIENTS AND METHODS: The prognostic significance of epidemiological, molecular genetic, and clinical data including treatment for glioblastoma patients diagnosed from 2010 to 2014 in the Canton of Zurich, Switzerland, was retrospectively analyzed using log-rank test and Cox proportional hazards models. Data were compared with data for the years 2005-2009. RESULTS: In total, 310 glioblastoma patients were identified in the years 2010-2014. Median overall survival was 13.5 months for patients with known isocitrate dehydrogenase (IDH) wild-type (wt) (IDH1R132H-non-mutant) tumors (N = 248), compared with 11.3 months for IDH wt patients (P = 0.761) before (2005-2009). In the IDH wt cohort, bevacizumab use at any time increased from 19% in 2005-2009 to 49% in 2010-2014. Multivariate analysis did not identify bevacizumab exposure at any time to be associated with survival. Yet, upon the second-line treatment, baseline doses of corticosteroids were reduced by more than half in 83% of patients on bevacizumab compared with 48% of the patients treated with bevacizumab-free regimens (P = 0.007). CONCLUSION: This epidemiological study of a small, but clinically well-annotated patient cohort fails to support the assumption that the strong increase of bevacizumab use since 2010 improved survival in glioblastoma although clinical benefit associated with decreased steroid use may have been achieved.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gramatzki D, Roth P, Rushing EJ, et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol. 2018. PMID: 29617713. doi:10.1093/annonc/mdy106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。